← Back to Screener
Ultragenyx Pharmaceutical Inc. (RARE)
Price$25.06
Favorite Metrics
Price vs S&P 500 (26W)-29.86%
Price vs S&P 500 (4W)15.37%
Market Capitalization$2.39B
All Metrics
Book Value / Share (Quarterly)$0.10
P/TBV (Annual)50.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)22.81%
Cash Flow / Share (Quarterly)$-5.04
Price vs S&P 500 (YTD)3.73%
Gross Margin (TTM)83.84%
Net Profit Margin (TTM)-85.47%
EPS (TTM)$-5.83
10-Day Avg Trading Volume1.67M
EPS Excl Extra (TTM)$-5.83
Revenue Growth (5Y)19.95%
EPS (Annual)$-5.83
ROI (Annual)-50.60%
Gross Margin (Annual)83.80%
Net Profit Margin (5Y Avg)-130.13%
Cash / Share (Quarterly)$7.04
Revenue Growth QoQ (YoY)25.55%
ROA (Last FY)-37.53%
Revenue Growth TTM (YoY)20.08%
EBITD / Share (TTM)$-5.07
ROE (5Y Avg)-141.85%
Operating Margin (TTM)-79.53%
Cash Flow / Share (Annual)$-5.04
P/B Ratio260.58x
P/B Ratio (Quarterly)316.50x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)4.64x
Net Interest Coverage (TTM)-14.43x
ROA (TTM)-43.07%
EPS Incl Extra (Annual)$-5.83
Current Ratio (Annual)2.48x
Quick Ratio (Quarterly)2.22x
3-Month Avg Trading Volume2.55M
52-Week Price Return-29.07%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.83
P/S Ratio (Annual)3.55x
Asset Turnover (Annual)0.44x
52-Week High$42.37
Operating Margin (5Y Avg)-118.69%
EPS Excl Extra (Annual)$-5.83
CapEx CAGR (5Y)-13.72%
Tangible BV CAGR (5Y)-31.88%
26-Week Price Return-21.11%
Quick Ratio (Annual)2.22x
13-Week Price Return3.07%
Total Debt / Equity (Annual)3.41x
Current Ratio (Quarterly)2.48x
Enterprise Value$3,119.65
Revenue / Share Growth (5Y)8.90%
Asset Turnover (TTM)0.50x
Book Value / Share Growth (5Y)-24.58%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.25x
Pretax Margin (Annual)-84.84%
Cash / Share (Annual)$7.04
3-Month Return Std Dev54.59%
Gross Margin (5Y Avg)89.47%
Net Income / Employee (TTM)$-0
ROE (Last FY)-222.95%
Net Interest Coverage (Annual)-14.65x
EPS Basic Excl Extra (Annual)$-5.83
Receivables Turnover (TTM)4.81x
Total Debt / Equity (Quarterly)90.54x
EPS Incl Extra (TTM)$-5.83
Receivables Turnover (Annual)4.81x
ROI (TTM)-58.61%
P/S Ratio (TTM)3.55x
Pretax Margin (5Y Avg)-129.67%
Revenue / Share (Annual)$6.83
Tangible BV / Share (Annual)$0.83
Price vs S&P 500 (52W)-64.17%
Year-to-Date Return7.87%
5-Day Price Return4.99%
EPS Normalized (Annual)$-5.83
ROA (5Y Avg)-38.33%
Net Profit Margin (Annual)-85.44%
Month-to-Date Return18.42%
Cash Flow / Share (TTM)$-8.66
EBITD / Share (Annual)$-5.33
Operating Margin (Annual)-79.49%
LT Debt / Equity (Annual)3.21x
ROI (5Y Avg)-73.69%
LT Debt / Equity (Quarterly)83.39x
EPS Basic Excl Extra (TTM)$-5.83
P/TBV (Quarterly)50.46x
P/B Ratio (Annual)15.22x
Inventory Turnover (TTM)2.25x
Pretax Margin (TTM)-84.88%
Book Value / Share (Annual)$2.76
Price vs S&P 500 (13W)0.21%
Beta0.36x
Revenue / Share (TTM)$6.74
ROE (TTM)-414.17%
52-Week Low$18.29
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.26
4.26
4.26
4.19
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RAREUltragenyx Pharmaceutical Inc. | 3.55x | 20.08% | 83.84% | — | $25.06 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Ultragenyx Pharmaceutical is a biopharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases. The company's marketed portfolio includes Crysvita (for X-linked hypophosphatemia) and Mepsevii (for Mucopolysaccharidosis VII), with additional therapies in development. Operating globally across North America, Europe, Asia-Pacific, and other regions, Ultragenyx generates the majority of its revenue from North America.